Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12882403 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX2NPY5RMAPTSMN1; SMN2 | |
| SCHEMBL10133461 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX2NPY5RMAPTSMN1; SMN2 | |
| SCHEMBL14424750 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX2NPY5RMAPTSMN1; SMN2 | |
| SCHEMBL10114739 | 0.90 | ALDH1A1 (0.47) | ALDH1A1EPHX2MAPTSMN1; SMN2LMNA | |
| SCHEMBL13204325 | 0.90 | ALDH1A1 (0.47) | ALDH1A1EPHX2MAPTSMN1; SMN2LMNA | |
| SCHEMBL10133411 | 0.90 | ALDH1A1 (0.47) | ALDH1A1EPHX2MAPTSMN1; SMN2LMNA | |
| SCHEMBL10133384 | 0.88 | ALDH1A1 (0.48) | ALDH1A1EPHX2NPY5RMAPTSMN1; SMN2 | |
| SCHEMBL14424742 | 0.88 | ALDH1A1 (0.48) | ALDH1A1EPHX2NPY5RMAPTSMN1; SMN2 | |
| SCHEMBL10134464 | 0.87 | LMNA (0.41) | ALDH1A1EPHX2MAPTSMN1; SMN2LMNA | |
| SCHEMBL10115599 | 0.87 | LMNA (0.41) | ALDH1A1EPHX2MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | ALDH1A1 4599/4885EPHX2 2527/4885NPY5R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.